Switzerland German biopharma giant Merck is investing EUR 250 million in a new Swiss biotech development facility; underscoring the company’s reliance on Switzerland for the manufacturing of advanced biologicals.   The Merck Biotech Development Center is to be located in Corsier-sur-Vevey, south-western Switzerland, close to the firm’s existing biotech commercial manufacturing…

Italy Italian mid-cap firm Chiesi is continuing its expansion in the USA market with the launch of a Boston-based subsidiary focusing on rare and ultra-rare diseases.   We are very excited to put Chiesi’s decades of experience in drug development and dedication to patients to work to make a positive difference…

Hungary In line with its status as one of Europe’s most dynamic economies, Hungary is aiming to boost both its life sciences industry and the level of healthcare it provides to its citizens.   Year-on-year GDP growth stood at 4.8 percent in 2019, driven on by a burgeoning domestic pharmaceuticals industry…

Germany Some of the top recent stories from Germany, Europe’s leading pharma market according to CPhI, including big new investments from Merck and Bayer, the implications of the country’s new Digital Healthcare Act, the impact of the coronavirus outbreak on investor sentiment, and the health minister potentially poised to become Germany’s…

UK Friday January 31 2020 was officially dubbed “Brexit Day” as the UK finally left the EU, following British Prime Minister Boris Johnson’s sweeping election victory on a promise to “Get Brexit Done”.   The UK now enters an 11-month transition period to disentangle political and economic ties from a single…

Belgium Over the past few decades, pharma multinationals have been increasingly drawn to the highly cost-competitive markets of Central Eastern Europe (CEE) and Asia to situate major manufacturing sites. However, despite a comparatively expensive location, Belgium’s strong industrial heritage and manufacturing expertise is helping to maintain the country as a strategic…

Romania State hospitals in Bucharest are increasingly overloaded with patients due to a lack of resources and specialists. This pressure is amplified by the fact that many Romanians turn to emergency services for even minor conditions. To rectify this situation, the Romanian state recently passed an emergency ordinance which allows private…

Belgium There are over 3.5 million diagnoses and 1.3 million deaths from cancer in the EU each year and cancer is set to become the region’s leading cause of death without a reversal of current trends. Against this backdrop, the European Commission is launching the ‘Europe’s Beating Cancer Plan’ to reduce…

Hungary Hungary’s longstanding tradition of pharmacology is a major point of pride for the country’s scientists and researchers who today have hopes to elevate the country’s research environment to a region-leading position once more through new models of industry-academia collaboration.   Strength in CNS Hungary has a very strong tradition in…

Hungary According to Peter Holchacker, director general of Hungary’s Association of Innovative Pharmaceutical Manufacturers (AIPM), “clinical trials initiated by multinational companies, represent, on average, an investment of approximately EUR 300 million each year.” Furthermore, Dr György Bodoky, founder and honorary president of the Hungarian Society of Clinical Oncology (MKOT), adds that…

Hungary Established in 1997, Medi-Radiopharma is a Hungarian privately held company operating in the field of nuclear medicine, a specialized area of radiology that uses very small amounts of radioactive materials, or radiopharmaceuticals, to examine organ function and structure. Breakthroughs in neurocranial and prostate tumour treatment have brought nuclear medicine into…

Hungary As general manager of the Hungarian affiliate of Swiss firm IBSA, Anna Wienner has proven herself to be a motivated pharma leader with particular expertise in reshaping and building organizations. Joining the company in 2015, Wienner took on her new position with the task of restructuring the stagnating affiliate. This…